What is Aignostics?
Aignostics operates at the intersection of artificial intelligence and clinical pathology, providing an interdisciplinary approach to the next generation of precision medicine. By utilizing sophisticated machine learning algorithms to analyze tissue samples, the company enables more accurate diagnostics and personalized treatment pathways. Its market position is defined by its ability to bridge the gap between complex biological data and actionable clinical insights, effectively serving as a vital partner for pharmaceutical companies and healthcare providers seeking to optimize drug development and patient outcomes.
How much funding has Aignostics raised?
Aignostics has raised a total of $48M across 2 funding rounds:
Series A
$14M
Series B
$34M
Series A (2022): $14M with participation from VC Fonds Technologie, High-Tech Gründerfonds, Boehringer Ingelheim Venture Fund, and Wellington Partners
Series B (2024): $34M led by IBB Ventures, Mayo Clinic, CARMA FUND Management, Boehringer Ingelheim Venture Fund, Wellington Partners, and ATHOS Holding
Key Investors in Aignostics
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund invests in pioneering science aimed at redefining care standards and developing new medicines for patients, focusing on first-in-class, disease-modifying therapeutics.
Wellington Partners
Wellington Partners is a leading European venture capital firm that invests in early- and growth-stage life science companies across various sectors, including therapeutics, medical devices, and diagnostics.
Mayo Clinic
Mayo Clinic is a nonprofit global healthcare organization specializing in integrated clinical practice, education, and medical research, bringing together specialists to address complex health conditions.
What's next for Aignostics?
With the successful closure of this major enterprise-level funding, Aignostics is poised to enter a phase of rapid commercial expansion and technological refinement. The strategic focus will likely shift toward scaling its AI pathology infrastructure to meet the increasing demand for high-throughput diagnostic tools. Furthermore, the involvement of specialized life science investors suggests a roadmap centered on deepening clinical partnerships and potentially expanding into new therapeutic areas where precision diagnostics are essential for regulatory approval and clinical efficacy. The company remains focused on solidifying its role as a foundational player in the digital health landscape.
See full Aignostics company page
